A Phase 2 Study of Lisocabragene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients with Agressive B-Cell NHL (017006)

Protocol No
JUNO-JCAR017-017006
Principal Investigator
Mehdi Hamadani
Phase
II
Summary
To evaluate the safety and effectiveness of a new approach to treat adults diagnosed with NHL, who have had their cancer come back or didn’t respond to one previous line of therapy and are not eligible to receive a stem cell transplant.
Description
Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (Transcend-Pilot-017006)
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: